Sanofi (NASDAQ:SNY) Shares Sold by Eagle Ridge Investment Management

Eagle Ridge Investment Management lowered its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 84.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,345 shares of the company's stock after selling 170,900 shares during the period. Eagle Ridge Investment Management's holdings in Sanofi were worth $1,609,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Transcend Capital Advisors LLC grew its stake in shares of Sanofi by 5.7% in the fourth quarter. Transcend Capital Advisors LLC now owns 5,730 shares of the company's stock worth $285,000 after acquiring an additional 307 shares during the last quarter. Unique Wealth Strategies LLC bought a new position in Sanofi in the 4th quarter worth about $577,000. Atria Wealth Solutions Inc. grew its position in Sanofi by 7.9% during the 4th quarter. Atria Wealth Solutions Inc. now owns 16,370 shares of the company's stock valued at $814,000 after purchasing an additional 1,205 shares during the last quarter. Wynn Capital LLC bought a new stake in Sanofi during the 4th quarter valued at about $251,000. Finally, Bfsg LLC purchased a new position in Sanofi in the fourth quarter worth about $71,000. Hedge funds and other institutional investors own 10.04% of the company's stock.

Sanofi Price Performance

Shares of SNY traded down $0.04 during mid-day trading on Monday, reaching $49.09. The stock had a trading volume of 3,285,409 shares, compared to its average volume of 2,011,168. The firm has a market cap of $124.18 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 1.48 and a beta of 0.61. Sanofi has a 12 month low of $42.63 and a 12 month high of $55.93. The business has a fifty day moving average of $47.77 and a 200 day moving average of $48.28. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to analysts' expectations of $13.02 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. Equities analysts predict that Sanofi will post 4.09 EPS for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. This represents a dividend yield of 2.98%. This is a boost from Sanofi's previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi's dividend payout ratio is 69.35%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SNY. StockNews.com downgraded shares of Sanofi from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 27th. Morgan Stanley initiated coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an "equal weight" rating and a $55.00 target price on the stock. Finally, TheStreet lowered shares of Sanofi from a "b" rating to a "c" rating in a research note on Friday, February 9th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.